UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2308-3
Program Prior Authorization/Medical Necessity
Medication Methyldopa
P&T Approval Date 6/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Methyldopa is an aromatic-amino-acid decarboxylase inhibitor indicated for hypertension.
The American Heart Association recommends methyldopa as a widely established first-line
option in the treatment of hypertension in pregnancy. Outside of pregnancy, methyldopa has
limited utilization due to significant adverse events.
2. Coverage Criteriaa:
A. Methyldopa will be approved based on both of the following criteria:
1. Patient is pregnant
-AND-
2. For the treatment of hypertension
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
4. References:
1. Methyldopa [package insert]. Conger, NY: Chartwell RX, LLC; November 2022.
2. Garovic VD, Dechend R, Karumanchi SA, et al. Hypertension in Pregnancy: Diagnosis, Blood
Pressure Goals, and Pharmacotherapy: A Scientific Statement from the American Heart
Association. Hypertension. 2022; 79: 321-e41.
3. Guideline for the pharmacological treatment of hypertension in adults. Geneva: World Health
Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
© 2025 UnitedHealthcare Services, Inc.
1
4. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report
of the American College of Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines.
Program Prior Authorization/Medical Necessity – Methyldopa
Change Control
6/2023 New program
5/2024 Annual review with no changes.
5/2025 Annual review with no changes.
© 2025 UnitedHealthcare Services, Inc.
2